Cargando…
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24
BACKGROUND: The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30–40% of patients are non-responders or relapsers to such combination. OBJECTIVE: To analyse t...
Autores principales: | Saadoun, David, Resche Rigon, M, Thibault, V, Longuet, M, Pol, S, Blanc, F, Pialoux, G, Karras, A, Bazin-Karra, D, Cazorla, C, Vittecoq, D, Musset, L, Decaux, O, Ziza, J M, Lambotte, O, Cacoub, Patrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995244/ https://www.ncbi.nlm.nih.gov/pubmed/23606708 http://dx.doi.org/10.1136/annrheumdis-2012-202770 |
Ejemplares similares
-
Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals
por: Comarmond, Cloé, et al.
Publicado: (2020) -
The Spectrum of Type I Cryoglobulinemia Vasculitis: New Insights Based on 64 Cases
por: Terrier, Benjamin, et al.
Publicado: (2013) -
Cardiac sarcoidosis: A long term follow up study
por: Cacoub, Patrice, et al.
Publicado: (2020) -
Ethnicity and association with disease manifestations and mortality in Behçet’s disease
por: Savey, Lea, et al.
Publicado: (2014) -
Leukocytoclastic Vasculitis in a Patient with Type 1 Cryoglobulinemia
por: Liu, Paul Y., et al.
Publicado: (2011)